BR112015000530A2 - vacina de antígeno micobacteriano. - Google Patents

vacina de antígeno micobacteriano.

Info

Publication number
BR112015000530A2
BR112015000530A2 BR112015000530A BR112015000530A BR112015000530A2 BR 112015000530 A2 BR112015000530 A2 BR 112015000530A2 BR 112015000530 A BR112015000530 A BR 112015000530A BR 112015000530 A BR112015000530 A BR 112015000530A BR 112015000530 A2 BR112015000530 A2 BR 112015000530A2
Authority
BR
Brazil
Prior art keywords
antigen vaccine
mycobacterial antigen
mycobacterial
vaccine
antigen
Prior art date
Application number
BR112015000530A
Other languages
English (en)
Inventor
Antoine Coupet Charles
Beny Cécile
Tupin Emmanuel
Inchaupse Geneviève
Marchand Jean-Baptiste
Gouanvic Marie
Silvestre Nathalie
Micol Romain
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of BR112015000530A2 publication Critical patent/BR112015000530A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
BR112015000530A 2012-07-10 2013-07-10 vacina de antígeno micobacteriano. BR112015000530A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12305825 2012-07-10
EP12306539 2012-12-07
EP13305737 2013-06-03
PCT/EP2013/064624 WO2014009438A2 (en) 2012-07-10 2013-07-10 Mycobacterial antigen vaccine

Publications (1)

Publication Number Publication Date
BR112015000530A2 true BR112015000530A2 (pt) 2018-08-28

Family

ID=48782326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000530A BR112015000530A2 (pt) 2012-07-10 2013-07-10 vacina de antígeno micobacteriano.

Country Status (17)

Country Link
US (1) US10357555B2 (pt)
EP (1) EP2872172B1 (pt)
JP (1) JP6333814B2 (pt)
KR (1) KR20150058152A (pt)
CN (1) CN104640564B (pt)
BR (1) BR112015000530A2 (pt)
CA (1) CA2878800A1 (pt)
EA (1) EA029492B1 (pt)
HK (1) HK1207962A1 (pt)
IL (1) IL236650B (pt)
MX (1) MX366206B (pt)
MY (1) MY173004A (pt)
SG (1) SG11201500171YA (pt)
TW (1) TWI638829B (pt)
UA (1) UA119228C2 (pt)
WO (1) WO2014009438A2 (pt)
ZA (1) ZA201500784B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009438A2 (en) * 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
EP4176897A1 (en) * 2013-06-25 2023-05-10 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
CN106103471B (zh) * 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 异源寡聚分枝杆菌抗原的融合
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN105601747B (zh) * 2015-10-21 2019-05-28 中山大学 一种结核杆菌融合蛋白及其在诱导外周血单个核细胞产生细胞因子的应用
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
JP2019521095A (ja) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CN109890411A (zh) 2016-06-16 2019-06-14 国际艾滋病疫苗行动组织公司 结核病组合物和治疗或预防结核病的方法
US11091775B2 (en) * 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
MX2019003035A (es) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
CN107236023B (zh) * 2017-05-12 2021-05-07 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
EP3697806A4 (en) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. TUBERCULOSIS ANTIGEN CASSETTES
WO2019210282A2 (en) * 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN109536431A (zh) * 2018-12-04 2019-03-29 江苏省农业科学院 复合生化复苏因子组合物及其应用
KR102135328B1 (ko) * 2018-12-19 2020-07-17 대한민국 결핵 2가 항원을 발현하는 약독화된 재조합 백시니아 바이러스 및 이를 포함하는 결핵 예방용 조성물
KR102157770B1 (ko) * 2019-01-11 2020-09-18 주식회사 파이지노믹스 가축의 결핵 진단을 위한 항원 펩타이드 조성물 및 이의 용도
CN109970183B (zh) * 2019-03-31 2021-01-15 浙江大学 一种复苏促进因子在印染废水处理中的应用及处理方法
BR112021025172A2 (pt) * 2019-06-14 2022-01-25 Statens Seruminstitut Proteínas de fusão para vacinas de tuberculose
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN110590957B (zh) * 2019-09-11 2021-06-01 中国人民解放军总医院第八医学中心 一种融合蛋白及其在抗结核分枝杆菌的免疫保护中的应用
RU2724896C1 (ru) * 2019-11-14 2020-06-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Полиантигенная вакцина для профилактики и вспомогательного лечения туберкулеза
CN111443208B (zh) * 2020-03-23 2024-01-19 中国医学科学院北京协和医院 鉴别活动性结核病和潜伏性结核病的组合物
WO2024023790A1 (en) * 2022-07-29 2024-02-01 University Of Cape Town Vaccine constructs comprising tuberculosis antigens
WO2024028445A1 (en) * 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024027910A1 (en) * 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN116162141B (zh) * 2022-11-30 2024-04-12 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原epcra013及其应用
CN116041543B (zh) * 2022-12-07 2023-12-26 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌多抗原融合蛋白及其编码基因和应用
CN116063418B (zh) * 2022-12-08 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原组合物epdpa015及其制备方法与应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6204026B1 (en) * 1997-11-05 2001-03-20 The Board Of Trustees Of The University Of Arkansas Detection of M. tuberculosis complex via reverse transcriptase SDA
US6892139B2 (en) * 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
JP4802366B2 (ja) 1999-02-22 2011-10-26 トランスジェン・ソシエテ・アノニム 精製ウイルス調製物の取得方法
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
ES2256323T5 (es) 2000-11-23 2016-11-21 Bavarian Nordic A/S Variante del virus Vaccinia Ankara Modificado
US7393539B2 (en) 2001-06-22 2008-07-01 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
JP2005508613A (ja) 2001-07-04 2005-04-07 ヘルス プロテクション エージェンシー 潜伏中に発現されるマイコバクテリア抗原
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
KR20040074067A (ko) 2001-12-10 2004-08-21 버베리안 노딕 에이/에스 폭스바이러스를 포함하는 제형 및 폭스바이러스를포함하는 안정한 조성물을 제조하기 위한 방법
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1523331B1 (en) 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
EP1606397A1 (en) 2003-03-17 2005-12-21 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
AU2003298554A1 (en) 2003-03-28 2004-11-23 Merck & Co., Inc. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
EP1711518B1 (en) 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Chimpanzee adenovirus vaccine carriers
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
BRPI0606165A2 (pt) 2005-01-05 2009-06-02 Isis Innovation método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
US20080311159A1 (en) 2005-03-31 2008-12-18 Michel Robert Klein Methods and Means for Diagnostics, Prevention and Treatment of Mycobacterium Infections and Tuberculosis Disease
EP1910409A2 (en) * 2005-06-23 2008-04-16 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
AU2007263281B2 (en) 2006-06-20 2012-12-06 Transgene S.A. Recombinant viral vaccine
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
MX351247B (es) * 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
AR065074A1 (es) 2007-05-15 2009-05-13 Transgene Sa Peptidos de senalizacion
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0811787B1 (pt) 2007-07-03 2018-10-09 Transgene Sa usos de uma célula imortalizada e processo para imortalizar uma célula aviária
GB0722105D0 (en) * 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
GB0906215D0 (en) * 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
EP2429580A1 (en) 2009-05-12 2012-03-21 Transgene SA Method for orthopoxvirus production and purification
ES2661215T3 (es) * 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
US20130101614A1 (en) * 2010-06-15 2013-04-25 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
EP2618838A1 (en) * 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
CA2811699C (en) * 2010-09-28 2019-07-02 Abera Bioscience Ab Fusion protein for secretory protein expression
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
US20130115240A1 (en) * 2011-11-09 2013-05-09 National Health Research Institutes Recombinant bcg strains with enhanced ability to inhibit intracellular mycobacterial growth
WO2014009438A2 (en) * 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
US20150211012A1 (en) * 2012-08-31 2015-07-30 Laboratorios Del Dr. Esteve S.A. Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
EP4176897A1 (en) * 2013-06-25 2023-05-10 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
CN106103471B (zh) * 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 异源寡聚分枝杆菌抗原的融合
GB201400819D0 (en) * 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
BR112016023778A2 (pt) * 2014-04-24 2017-10-17 Statens Seruminstitut proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
MX2017003017A (es) * 2014-09-09 2018-02-19 Virginia Tech Intellectual Properties Inc Vacuna multivalente de brucella para la proteccion contra infecciones micobacterianas y metodos para su uso.
CN109890411A (zh) * 2016-06-16 2019-06-14 国际艾滋病疫苗行动组织公司 结核病组合物和治疗或预防结核病的方法
US11091775B2 (en) * 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis

Also Published As

Publication number Publication date
SG11201500171YA (en) 2015-02-27
CN104640564A (zh) 2015-05-20
IL236650A0 (en) 2015-02-26
UA119228C2 (uk) 2019-05-27
MX2015000449A (es) 2015-07-14
WO2014009438A2 (en) 2014-01-16
TWI638829B (zh) 2018-10-21
IL236650B (en) 2019-09-26
EP2872172A2 (en) 2015-05-20
ZA201500784B (en) 2020-07-29
CA2878800A1 (en) 2014-01-16
JP2015524794A (ja) 2015-08-27
TW201408691A (zh) 2014-03-01
HK1207962A1 (en) 2016-02-19
MY173004A (en) 2019-12-18
EA029492B1 (ru) 2018-04-30
KR20150058152A (ko) 2015-05-28
EA201590184A1 (ru) 2015-06-30
US20150165014A1 (en) 2015-06-18
EP2872172B1 (en) 2018-11-14
CN104640564B (zh) 2020-08-04
JP6333814B2 (ja) 2018-05-30
US10357555B2 (en) 2019-07-23
WO2014009438A3 (en) 2014-04-10
MX366206B (es) 2019-07-02

Similar Documents

Publication Publication Date Title
BR112015000530A2 (pt) vacina de antígeno micobacteriano.
CL2016000680A1 (es) Formulaciones de anticuerpos anti-pdl1.
BR112015008635A2 (pt) anticorpos anti-hiv amplamente neutralizantes.
BR112014033077A2 (pt) combinação de vacina.
DK2934584T3 (da) Anti-gdf15-antistoffer
DK2850101T3 (da) Anti-FcRn-antistoffer
DK3117837T3 (da) Antistofformuleringer
BR112014032116A2 (pt) método.
DK3275892T3 (da) Præfusions-rsv-f-antigener
DK2992020T3 (da) Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
DK2858671T3 (da) Antistofformulering
DK2906251T3 (da) Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
BR112015008232A2 (pt) conjugados pirrolbenzodiazepina-anticorpo
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
DK2858676T3 (da) Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater
DK2651436T3 (da) Mycobakterie antigen sammensætning.
BR112013020383A2 (pt) formulações liofilizadas.
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
BR112015002960A2 (pt) aparelho de gravação.
BR112015013892A2 (pt) simulador.
BR112014005756A2 (pt) vacina
BR112014028871A2 (pt) linhagens de propionibacterium.
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK3431504T3 (da) Antiphospholipase d4-antistof
DK3062824T3 (da) Telomerase-kodende dna-vaccine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements